# China NMPA Drug Inspection - Hubei Renyue Pharmaceutical Co., Ltd. - Chlorpheniramine maleate tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hubei-renyue-pharmaceutical-co-ltd/72bfc3d9-8c8c-4d64-9ae3-cb1ed9d4566d/
Source feed: China

> China NMPA drug inspection for Hubei Renyue Pharmaceutical Co., Ltd. published July 16, 2021. Drug: Chlorpheniramine maleate tablets. 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Yunnan Provincial Drug Administration issued the second issue of the 2021 Drug Quality Bulletin.
- Company Name: Hubei Renyue Pharmaceutical Co., Ltd.
- Publication Date: 2021-07-16
- Drug Name: Chlorpheniramine maleate tablets
- Inspection Finding: The product does not meet the requirements; the non-compliant item is [property].
- Action Taken: The samples were inspected and found to be qualified by the local regulatory authorities and the samples retained by the manufacturer.

Company: https://www.globalkeysolutions.net/companies/hubei-renyue-pharmaceutical-co-ltd/4b714f60-8708-4436-839a-fab1117d6a4a/